Other reported cases
7,863,126 cases
5 days × average intensity 3
7,863,126 × 5 × 24 × 3 ÷ 47.25
≈ 7.6 USU per caseEstimated total for this group: about 59.9 million USU.
Disease outbreak
Experimental estimate · v0.11Report prepared 8 October 2026
Acute illness, including fatal cases
Same reporting period. Source context
reported cases
1 USU is the modeled burden of one specified six-hour kidney-stone pain reference. It is a common reporting unit, not a claim that the experiences feel the same.
Approximate, assumption-based USU for the included experience. Deaths are a separate measure. Includes fatal illness.
Reading the result
About 60.0 million USU is assigned to 7,866,769 reported cases in this snapshot. The estimate combines an ordinary acute course for 7,863,126 other reported cases with a complete fatal illness course for 3,643 reported deaths. All dengue entries use the same two courses. Source coverage and the number of cases in each group still differ.
Population count × modeled average ≈ total USU
This is a modeled average across the included cases. Other reported cases are assigned about 7.6 USU each; reported fatal cases are assigned about 17.8 USU each. Each course is weighted by its case count. The average can differ between outbreaks because the reported mix of cases differs, even when the same course assumptions are used. See the two courses and their assumed durations →
This is an assumption-based average, not an observed average or a prediction for any individual. Figures shown here are rounded; calculations use unrounded values. How to read these averages.
Fatal-case duration comes from historical studies in other settings, not measurements in this outbreak. The average intensity is an author-selected assumption. Clinical severity and conscious time are not reconstructed; persistent symptoms remain unestimated.
The calculation
7,866,769 reported cases = 7,863,126 other reported cases + 3,643 reported fatal cases. “Other” includes unresolved outcomes and does not mean known survivors or mild cases.
7,863,126 cases
5 days × average intensity 3
7,863,126 × 5 × 24 × 3 ÷ 47.25
≈ 7.6 USU per caseEstimated total for this group: about 59.9 million USU.
3,643 cases
7 days × average intensity 5
3,643 × 7 × 24 × 5 ÷ 47.25
≈ 17.8 USU per caseEstimated total for this group: about 64.8 thousand USU.
Rounded for readability. The downloadable inputs retain the calculation precision.
The fatal course replaces the ordinary allowance for those same cases. It covers the complete illness ending at death, so there is no additional terminal-period charge. Death itself, lost life years and bereavement are not assigned USU.
All dengue reports use these same two courses. Differences come from the reported case and death counts and their coverage, not country-specific intensity judgments.
Intensity is a combined 0–10 average over the elapsed course, including relief, sleep and intervals without experience. No intensity is assigned after death or to known absence of experience. Why divide by 47.25?
The existing five-day acute course is retained for cases not reported dead at the snapshot cutoff. WHO gives a 2-7-day symptom window. Five days is a representative choice, not a measured mean or a survivor-specific estimate. Other cases include unresolved outcomes and severe cases not reported dead; no future deaths are imputed. Later fatigue is excluded. [S2]
Fever, headache, body/joint aches and nausea support a meaningful acute symptom burden. Assigned intensity 3 is a working average across the whole day, including relief and sleep. It is lower than a severe-pain peak. WHO does not establish the value 3 or its ratio to the reference. [S2]
Seven days is a provisional representative course from symptom onset to death. A Puerto Rico series of 58 fatal laboratory-positive cases reported a median of 7.1 days; in a Malaysian review of 322 deaths, 66.5% occurred on illness days 4-7. A Singapore series of 28 adults reported a longer median of 12 days. These differing populations support testing alternatives. Seven days is our choice, not a pooled mean or an observed average for the listed outbreaks. [S18] [S19] [S20]
We assign intensity 5 as one combined average for pain and other experienced distress throughout the fatal illness. Clinical descriptions of abdominal pain, vomiting and breathing difficulty motivate testing a higher average than the ordinary value 3. The exact value 5 and its ratio to 3 are judgments, not measured USU conversions. This elapsed-time average allows for earlier milder illness, treatment, relief, sleep and periods without experience; it is not a constant severe-pain score. [S17]
Version 0.4 assigned the same 5-day, intensity-3 course to all 7,866,769 cases: 59,937,287.62 USU. The revised estimate is 59,974,295.87 USU, a change of +37,008.25 USU (+0.062%).
For the 3,643 reported fatal cases, 27,756.19 USU is removed and replaced with 64,764.44 USU. The reference unit and source counts are unchanged.
Testing the assumptions
Under the central assumptions, other reported cases contribute 99.9%; reported fatal cases contribute 0.1% of the total. Both courses are varied below.
Each row uses the same reported counts and included experiences. The lower and higher rows change duration and intensity together for every included course.
| Scenario | Assumed courses | Estimated USU |
|---|---|---|
| Lower assumptions | Other reported cases: 2 days at intensity 2 Reported fatal cases: 5 days at intensity 4 | 16.0 million |
| Central assumptions | Other reported cases: 5 days at intensity 3 Reported fatal cases: 7 days at intensity 5 | 60.0 million |
| Higher assumptions | Other reported cases: 7 days at intensity 4 Reported fatal cases: 12 days at intensity 6 | 112 million |
These are alternative assumptions, not confidence intervals or bounds. Counts can be incomplete or misclassified; omitted experiences and the validity of the intensity scale remain outside this calculation. Actual burden could fall outside these examples.
Only the named input changes. Every other duration, intensity and count stays at its central value. Each result is the total for the whole report.
| Input varied | Lower input and resulting total | Higher input and resulting total |
|---|---|---|
| Other reported cases Duration | 2 days 24.0 million USU | 7 days 83.9 million USU |
| Other reported cases Average intensity | 2 / 10 40.0 million USU | 4 / 10 79.9 million USU |
| Reported fatal cases Duration | 5 days 60.0 million USU | 12 days 60.0 million USU |
| Reported fatal cases Average intensity | 4 / 10 60.0 million USU | 6 / 10 60.0 million USU |
Fatal illness remains a replacement course for the same reported fatal cases; no case is counted twice. How the scenarios are chosen.
Download scenario calculations (CSV) · Reproduce the scenarios (Python)
Coverage
One complete acute illness course per reported case, combining pain and other acute distress. The 3,643 cases reported dead receive a seven-day, intensity-5 fatal course; the other 7,863,126 cases retain the five-day, intensity-3 assumption. Other cases include unresolved outcomes and severe cases not reported dead. They are not all known survivors or mild cases.
PAHO/WHO, 18 June 2024, p. 6: 7,866,769 reported cases through EW 23. The regional surveillance series includes suspected cases; this is not a laboratory-confirmed-only count. No correction for missed or misclassified cases is applied. [S1]
Later fatigue, prolonged recovery, a separate severity adjustment for other reported cases, caregiver distress, bereavement, unreported infections, death itself and lost life years.
Omitted experiences are unestimated, not known to be zero. This is not a complete event total or a guaranteed lower bound.
Whole representative courses are assigned to the source-defined cases or cohort. Course time can extend beyond the reporting dates. The fatal course ends at death; individual symptom histories and timing are not reconstructed. Other cases include unresolved outcomes, and no future deaths are imputed. No causal baseline or suffering after death is assigned.
Deaths remain separate
3,643 reported fatal cases are used within the 7,866,769-case population to select a complete fatal illness course. Those cases are removed from the ordinary group, and the death count remains separately visible. [S1]
A complete fatal illness course is included for 3,643 source-defined fatal cases. It replaces their ordinary allowance; each case receives one course. This does not cover every possible death or consequence.
Why this death count fits the calculation: PAHO country detail on page 6 reports 7,866,769 cases and 3,643 fatal cases through EW 23 of 2024, with the fatality rate using that case population. [S1]
USU estimates experienced suffering during lived time. Death itself and lost life years are not assigned USU. A report can use a death count to identify a distinct course of suffering before death, as in the disease fatal-course calculations. Bereavement remains unestimated.
Trace the estimate
Reported cases, deaths and coverage for Brazil, Peru and Mexico. These counts do not establish USU intensities.
Acute symptom descriptions and 2-7-day duration context; does not estimate an average USU intensity.
Stipulated six-hour kidney-stone reference: 47.25 modeled intensity-hours, with linear weighting. This convention defines the unit; it is not a measured equivalence between conditions.
Describes febrile and critical phases, abdominal pain, vomiting, respiratory distress and severe complications. Does not establish a USU intensity or complete fatal-course average.
58 fatal laboratory-positive cases; median onset-to-death interval 7.1 days, range 1.2-28.4. Historical duration context; comorbidities and some coinfections limit attribution and transfer to other outbreaks.
National retrospective review of 322 deaths; 66.5% occurred on illness days 4-7. Supports a roughly week-long scenario, not a universal duration or USU mapping.
28 adult fatal cases; median onset-to-death duration 12 days, range 2-38. Provides a longer-course contrast and motivates a duration alternative; selected hospital population with frequent comorbidity.
Understanding suspected, confirmed and severe dengue counts →
This guide explains the measures; its places and reporting period differ from this estimate.